Literature DB >> 19857685

Correlation between selected prognostic factors and postoperative course in liver transplant recipients.

W Patkowski1, K Zieniewicz, M Skalski, M Krawczyk.   

Abstract

AIM: The objective was to identify the major prognostic factors influencing liver function after transplantation that predict the postoperative course and long-term survival among liver transplant recipients. We analyzed the results of biochemical, microbiological, serologic, and pathologic studies of the donor and recipient, as well as intraoperative data.
MATERIALS AND METHODS: Of 542 liver transplant recipients, 215 (39.7%) were analyzed in the period from 1989 to 2006. Patients were divided according to the mechanism leading to the liver disease: group I, hepatitis C virus (HCV) infection (n = 80, 37.0%); group II, hepatitis B virus (HBV) infection (n = 33, 15.0%); group III, HBV and HCV infection (n = 13, 6.0%); group IV, alcoholic liver disease (ALD) (n = 66, 31.0%); and group V, autoimmune hepatitis (AIH) (n = 23, 11.0%).
RESULTS: Prediction of patient survival based on clinical parameters showed a better prognostic value than that based only on liver function tests. Transplant urgency scores-Model for End-Stage Liver Disease (MELD), delta MELD and United Network for Organ Sharing (UNOS)-enabled us to predict early and long-term patient survival after liver transplantation. Update of these scores, reflecting the patient's condition, enabled us to evaluate pretransplant life-threatening factors and urgency level. Organ donation predictive factors were age, viral status, and degree of liver steatosis. Cold and warm ischemia times still were major prognostic factor. Routine biliary drainage resulted in worse long-term survival than non-drained patients. Liver transplantation for ALD showed the highest complication rate. Chronic liver rejection occurred more frequently in the AIH transplanted group. The most useful predictive factors for 1-year survival were urea/creatinine and liver function tests: aspartate and alanine aminotransferases, gamma-glutamyl transpeptidase the International normalized ratio, and Quick.
CONCLUSION: The prognosis of patient outcomes after liver transplantation based on clinical parameters showed greater value than evaluation of the laboratory data.

Entities:  

Mesh:

Year:  2009        PMID: 19857685     DOI: 10.1016/j.transproceed.2009.09.038

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  4 in total

1.  Oil Red O-assessed macrosteatosis in liver transplant donor biopsies predicts ischemia-reperfusion injury and clinical outcome.

Authors:  Henning Reis; Patricia T Peterek; Jeremias Wohlschlaeger; Gernot M Kaiser; Zoltan Mathe; Benjamin Juntermanns; Georgios C Sotiropoulos; Ulrich Beckhove; Ali Canbay; Ulrike Wirges; Andre Scherag; Juergen-Walter Treckmann; Andreas Paul; Hideo Andreas Baba
Journal:  Virchows Arch       Date:  2013-12-03       Impact factor: 4.064

2.  Factors associated with long-term survival after liver transplantation: A retrospective cohort study.

Authors:  Sven Pischke; Marie C Lege; Moritz von Wulffen; Antonio Galante; Benjamin Otto; Malte H Wehmeyer; Uta Herden; Lutz Fischer; Björn Nashan; Ansgar W Lohse; Martina Sterneck
Journal:  World J Hepatol       Date:  2017-03-18

3.  Post-operative hypertension, a surrogate marker of the graft function and predictor of survival in living donor liver transplant recipients: A retrospective study.

Authors:  Manish Tandon; Anshuman Singh; Vandana Saluja; Gaurav Dubey; Vijay Kant Pandey; Chandra Kant Pandey; Sunaina Tejpal Karna; Shweta A Singh
Journal:  Indian J Anaesth       Date:  2016-07

4.  Predictors of early recipient mortality after living donor liver transplantation in a tertiary care center in Egypt.

Authors:  Mohammed A Nafea; Ayman Alsebaey; Ahmed Abd El Aal Sultan; Mohammed Hisham Goda; Ahmed Salman; Hanaa Said Rashed; Ahmed Soliman; Mai Elshenoufy; Mostafa Abdelrahman
Journal:  Ann Saudi Med       Date:  2019-10-03       Impact factor: 1.526

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.